证券代码：002173 证券简称：*ST 创疗 创新医疗管理股份有限公司投资者关系活动记录表 编号：2016-04 | --- | --- | --- | |----------------------------------------|------------------------------|------------------------------------------------------------------------------| | | | | | | | | | 投资者关系活动类别 | □ 特定对象调研 | □ 分析师会议 | | | √ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及人员姓名 | 诸暨日报胡子昂、冯杭洁 | | | 时间 | 2016 年 12 月 2 日 | 上午 10:00 至 11:30 | | 地点 | 公司五楼会议室 | | | 上市公司接待人员姓名 | | 副总裁兼董事会秘书傅震刚、证券事务代表张玉兰 | | 现场调研活动主要内容介绍： | | ...

创新医疗管理股份有限公司 投资者关系活动记录 创新医疗管理股份有限公司 投资者关系活动记录表 | --- | --- | |--------------------|------------------------------------------------------------------------------------------------| | | | | | √ 公司现场接待 □ 电话接待 | | 投资者关系活动类别 | □ 其他场所接待 □ 公开说明会 | | | □ 定期报告说明会 □ 重要公告说明会 | | | □ 其他（请文字说明其他活动内容） | | | 浙江广电集团广播经济频道《走进上市公司》栏目组 | | 参与单位及人员姓名 | （5 人）：陈正忠、李耸、张舒、庄严、周凤娣 个人投资者（ 6 人）：徐文煊、何煦能、卞央维、蔡 | | | 家超、朱睿莹、贺韵琴 | | 时间 | 2018 年 9 月 20 日 | | 地点 | 杭州市西湖区求是路 8 号公元大厦北楼 303A | | | 副总经理兼董事会秘书 田金明 | | 上市公司接待人员 | 证券部 季仕才、郭立丹 | | ...

证券代码：002173 证券简称：创新医疗 公告编号：2022-066 创新医疗管理股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1、董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2、公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证 季度报告中财务信息的真实、准确、完整。 3、第三季度报告是否经过审计 创新医疗管理股份有限公司 2022 年第三季度报告 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比 上年同期增减 | 年初至报告期末 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | | | 增减 | | 营业收入（元） | 204,978,861.32 | 23.52% | 540,574,309.85 | 1.23% | | ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥335,595,448.53, a decrease of 8.82% compared to ¥368,050,497.79 in the same period last year[17]. - The net loss attributable to shareholders was ¥48,076,544.67, representing a 119.27% increase in losses compared to a net loss of ¥21,925,534.04 in the previous year[17]. - Basic and diluted earnings per share were both -¥0.11, reflecting a 120.00% increase in losses compared to -¥0.05 in the previous year[17]. - The company reported a total revenue of approximately CNY 860.19 million for the first half of 2022, with a net profit of CNY 130.35 million, reflecting a decrease of CNY 6.76 million compared to the previous period[59]. - The total comprehensive loss for the first half of 2022 was approximately ¥48.29 million, compared to a comprehensive income of ¥26.36 million in the first half of 2021, marking a significant decline[169]. - The total revenue for the first half of 2022 was reported at 453,609,000 CNY, reflecting a significant increase compared to the previous period[126]. - The company reported a net profit margin of 8% for the first half of 2022, indicating a stable profitability level[126]. Cash Flow and Assets - The net cash flow from operating activities was -¥85,618,564.22, a significant decline of 3,315.37% from a positive cash flow of ¥2,662,791.59 in the same period last year[17]. - The company reported a substantial increase in cash flow from investment activities, reaching ¥512,424,232.05, up 891.25% year-on-year, mainly due to the redemption of financial products[32]. - The company's cash and cash equivalents increased significantly to CNY 649,818,356.30, accounting for 27.17% of total assets, up from 9.45% the previous year[39]. - The total assets at the end of the reporting period were ¥2,391,736,905.46, down 6.43% from ¥2,556,184,699.61 at the end of the previous year[17]. - The company's accounts receivable increased to CNY 119,965,915.84, representing 5.02% of total assets, up from 3.49% the previous year[39]. - The total current liabilities decreased to CNY 239.66 million from CNY 307.83 million, a reduction of approximately 22.1%[158]. Operational Challenges - Total operating revenue for the reporting period was ¥335,595,448.53, down 8.82% compared to the previous year, primarily due to the ongoing impact of the pandemic and related control measures[32]. - The company faces significant risks and challenges, which are detailed in the section on risks and countermeasures in the report[4]. - The ongoing impact of the pandemic has resulted in structural changes in hospital operations, with the company implementing strategies to maintain effective epidemic prevention measures[62]. - The company reported a decrease in inventory to CNY 32,986,364.51, which accounted for 1.38% of total assets, down from 1.80% the previous year[39]. Strategic Initiatives - The company plans to enhance its core competitiveness through refined management and the introduction of specialized medical talents across its hospitals[29]. - The company is actively adapting to changes in healthcare policies to enhance service quality and meet the evolving demands of the healthcare sector[60]. - The company is focusing on retaining and attracting medical talent by improving incentive systems and enhancing employee training and satisfaction[64]. - The company plans to expand its market presence and invest in new product development to drive future growth[177]. Social Responsibility and Compliance - The company has conducted over 14 free medical consultation events, serving approximately 1,100 individuals in the first half of 2022, promoting health awareness and disease prevention[88]. - The company has supported over 30 community nucleic acid testing points, conducting sampling for more than 1.14 million individuals since May 2022, demonstrating commitment to public health during the pandemic[85]. - The company has established a medical waste management system, ensuring proper storage, handling, and disposal of medical waste, with regular training for staff on waste management protocols[76]. - The company has maintained transparency and compliance with legal regulations, ensuring timely and accurate information disclosure to protect shareholder and creditor rights[80]. Legal and Regulatory Matters - The company is currently involved in arbitration regarding the performance compensation dispute, and the outcome remains uncertain[93]. - The company reported a contingent liability of 130,420,805.20 RMB related to a financing lease dispute with Baoxin International[98]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[94]. - The company has not undergone any bankruptcy reorganization during the reporting period[105]. Shareholder and Equity Information - The total number of shares outstanding after the changes was 372,252,021, with 81.85% being unrestricted shares[131]. - The company repurchased and canceled a total of 1,246,735 shares at a total price of 1 CNY, with an additional 530,047 shares repurchased and canceled in February 2022[132]. - The company’s stockholders have not proposed any applications for lifting restrictions on shares, and related procedures have not been processed[139]. - The total number of ordinary shareholders at the end of the reporting period was 30,819[142].

Financial Performance - The company's operating revenue for 2021 was ¥711,515,518.12, a decrease of 1.76% compared to ¥724,243,049.01 in 2020[20] - The net profit attributable to shareholders was -¥105,225,864.63, an improvement of 66.54% from -¥314,501,943.35 in the previous year[20] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥91,724,759.57, showing a 65.66% increase compared to -¥267,074,741.63 in 2020[20] - The net cash flow from operating activities was ¥43,370,331.70, a decline of 67.06% from ¥131,665,941.48 in 2020[20] - The basic earnings per share improved to -¥0.23, up 66.67% from -¥0.69 in the previous year[20] - The diluted earnings per share for 2021 was -0.23 CNY, an improvement of 66.67% compared to -0.69 CNY in 2020[21] - The total assets at the end of 2021 were 2,556,184,699.61 CNY, a decrease of 4.53% from 2,677,542,017.40 CNY at the end of 2020[21] - The net assets attributable to shareholders decreased by 7.17% to 1,989,808,178.69 CNY at the end of 2021 from 2,143,437,756.92 CNY at the end of 2020[21] - The company reported a net cash flow from operating activities of -9,888,396.53 CNY in Q1 and 12,551,188.12 CNY in Q2, indicating fluctuations in cash flow[25] Strategic Transformation - The company has undergone a strategic transformation to focus on high-quality medical services, moving away from its previous pearl-related business[19] - The company completed a major asset restructuring in 2016, adding three subsidiaries in the medical service sector[19] - The company is focusing on expanding its core departments and enhancing service quality to improve patient care[33] - The company aims to enhance its management capabilities through refined management practices and improve operational efficiency[33] Hospital Performance - Jianhua Hospital's revenue was 399.88 million yuan, a year-on-year decline of 6.64%, while the net profit was -94.83 million yuan, with a year-on-year reduction in losses of 60.79%[38] - Kanghua Hospital reported revenue of 292.69 million yuan, a year-on-year increase of 3.87%, but the net profit decreased by 46.95% to 5.74 million yuan[39] - Futen Hospital's revenue reached 15.74 million yuan, a year-on-year increase of 11.30%, with a net profit of -13.58 million yuan, reducing losses by 14.39%[41] - Mingzhu Hospital generated revenue of 74.22 million yuan, a year-on-year increase of 16.93%, while the net profit was -7.82 million yuan, a year-on-year decrease of 3.08%[42] Government and Regulatory Compliance - The audit report for the annual report was issued with a qualified opinion by Lixin Certified Public Accountants[5] - The company has fulfilled its information disclosure obligations regarding fundraising management and has no violations in this area[94] - The company has not faced any significant discrepancies in governance compared to regulatory requirements[121] - The company has not reported any non-operating fund occupation by controlling shareholders or other related parties during the reporting period[183] Legal and Financial Matters - The company is actively involved in legal proceedings to recover funds and address disputes with financial institutions[89] - A court ruling mandated the return of 24,969,028.26 to the company from the bank, along with interest calculated at a rate of 0.3%[88] - The company reached a settlement agreement with Baoxin International regarding a financing lease contract dispute, which has been approved by the shareholders' meeting[200] - The total amount involved in the financing lease contract dispute with Baoxin International was approximately 778.99 million[200] Research and Development - The company is exploring potential acquisitions to bolster its technology capabilities, with a budget of 500 million RMB allocated for this purpose[134] - The company is currently in the R&D investment phase for Boling Technology and does not expect to generate business revenue in the short term[114] - The first generation prototype of the BCI technology for assisting stroke patients has been successfully developed, with further research and development ongoing[113] Employee and Governance - The company has established a transparent performance evaluation and incentive mechanism for directors and senior management, ensuring compliance with legal standards[119] - The company reported a total of 587 doctors, 996 nurses, and 329 medical technicians among its employees[155] - The company has a structured salary policy that links employee performance with economic benefits, aiming to motivate staff[156] - The company has implemented various corrective measures to enhance environmental awareness and management practices across its subsidiaries[169] Social Responsibility and Community Engagement - The company organized free medical consultations for over 3,000 individuals in impoverished rural areas in 2021, distributing free medications and masks[176] - The company participated in COVID-19 prevention efforts, mobilizing over 200 medical staff for various tasks, including 7 city-wide nucleic acid testing events and 3 vaccination campaigns[175] - The company has received multiple commendations from health authorities for its effective management and layout of vaccination sites during the pandemic[176] Future Outlook - The company plans to continue expanding its market presence through new projects and investments in healthcare facilities[80] - The company provided guidance for the next fiscal year, projecting a revenue growth of 25% to 1.875 billion RMB[136] - The management emphasized a commitment to sustainability, with plans to reduce carbon emissions by 15% by 2025[134]

Financial Performance - The company's revenue for Q1 2022 was ¥171,290,921.92, representing a 6.13% increase compared to ¥161,392,113.23 in the same period last year[4] - The net profit attributable to shareholders was -¥14,238,149.54, an improvement of 40.81% from -¥24,053,643.08 year-on-year[4] - The company's basic earnings per share were -¥0.03, improving by 40.00% from -¥0.05 in the same period last year[4] - The weighted average return on equity was -0.72%, an improvement of 0.42% from -1.14% year-on-year[4] - Total operating revenue for Q1 2022 was CNY 171,290,921.92, an increase of 6.4% compared to CNY 161,392,113.23 in Q1 2021[19] - Net loss for Q1 2022 was CNY 14,211,186.74, an improvement from a net loss of CNY 24,022,128.39 in Q1 2021[20] - The company reported a gross profit margin of approximately -10.5% for Q1 2022, compared to -8.5% in Q1 2021[20] - Basic and diluted earnings per share for Q1 2022 were both negative CNY 0.03, an improvement from negative CNY 0.05 in Q1 2021[20] Cash Flow and Operating Activities - The net cash flow from operating activities was -¥72,743,214.00, a significant decline of 635.64% compared to -¥9,888,396.53 in the previous year[4] - The company experienced a 73.60% decrease in cash received from operating activities, totaling ¥3,926,240.98 compared to ¥14,873,610.04 in the previous year[10] - Operating cash flow for Q1 2022 was negative CNY 72,743,214.00, compared to negative CNY 9,888,396.53 in the same period last year[23] - Cash and cash equivalents at the end of Q1 2022 totaled CNY 132,404,379.55, down from CNY 276,245,532.99 at the end of Q1 2021[24] - The company's cash and cash equivalents decreased from ¥225,710,845.59 to ¥132,404,379.55, a decline of about 41.29%[15] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,445,530,025.68, down 4.33% from ¥2,556,184,699.61 at the end of the previous year[4] - The company's total assets at the end of the reporting period amount to ¥2,445,530,025.68, down from ¥2,556,184,699.61 at the beginning of the year, representing a decrease of approximately 4.34%[16] - Total current assets decreased from ¥940,020,380.04 to ¥845,644,918.27, a decline of about 10.03%[16] - Total current liabilities decreased from ¥345,968,853.24 to ¥283,117,970.20, a reduction of approximately 18.14%[17] - The company has a total liability of ¥468,824,977.29, down from ¥565,268,463.48, indicating a decrease of approximately 17.14%[17] - The company's total liabilities decreased by 24.59% to ¥98,345,176.53, primarily due to repayments of long-term borrowings[10] Shareholder Information - The total number of common shareholders at the end of the reporting period is 41,312, with no preferred shareholders having restored voting rights[12] - The largest shareholder, Chen Xiaying, holds 17.13% of shares, amounting to 77,616,997 shares, with 37,700,000 shares pledged[12] Expenses and Other Income - The company reported a significant increase in sales expenses, which rose by 99.34% to ¥2,218,957.65 due to increased marketing efforts in its subsidiary[10] - Other income increased by 260.49% to ¥1,002,214.14, primarily due to increased government subsidies received[10] - Total operating costs for Q1 2022 were CNY 190,078,948.39, up 4.5% from CNY 182,033,255.24 in the previous year[19] - The company incurred research and development expenses, although specific figures were not disclosed in the report[19] Future Plans and Audit Status - The company plans to focus on market expansion and new product development in the upcoming quarters[20] - The report was not audited, indicating that the figures may be subject to change upon further review[25]

Financial Performance - The company's operating revenue for Q3 2021 was ¥165,953,226.42, a decrease of 19.77% compared to the same period last year[4] - The net profit attributable to shareholders was -¥14,091,681.55, representing a decline of 453.17% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥17,204,749.55, a decrease of 171.27% compared to the previous year[4] - The basic earnings per share for Q3 2021 was -¥0.03, a decline of 400.00% year-on-year[4] - The diluted earnings per share for Q3 2021 was also -¥0.03, reflecting the same percentage decline[4] - Total operating revenue for the current period is $534.00 million, an increase from $522.43 million in the previous period, representing a growth of approximately 2.9%[27] - Net profit for the current period is -$35.89 million, an improvement from -$49.35 million in the previous period, indicating a reduction in losses of approximately 27.3%[28] - Operating profit improved to -$18.03 million from -$58.25 million, showing a significant reduction in operating losses[27] - Basic and diluted earnings per share improved to -$0.08 from -$0.11 in the previous period[28] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was ¥47,176,000.84, down 34.95% from the same period last year[10] - Cash flow from operating activities generated a net amount of $47.18 million, down from $72.53 million in the previous period[31] - Cash flow from investing activities resulted in a net outflow of -$15.06 million, an improvement compared to -$620.35 million in the previous period[32] - Cash and cash equivalents decreased to RMB 298,110,999.04 from RMB 346,273,312.01, a decline of approximately 13.9%[23] - Cash and cash equivalents at the end of the period totaled $292.11 million, slightly up from $286.16 million in the previous period[32] Shareholder Information - The company reported a total of 17,939 common shareholders at the end of the reporting period[12] - The top shareholder, Chen Xiaying, held 17.11% of the shares, amounting to 77,616,997 shares, with 37,700,000 shares pledged[12] - The company has a total of 10 major shareholders, with the top three holding 18.3% of the total shares[13] - The company reported a cash dividend return of RMB 178,116.71 and has compensated 1,246,735 shares, with 530,047 shares remaining to be compensated[18] Legal and Regulatory Issues - The company is pursuing arbitration regarding compensation obligations from Kanghan Investment, which has yet to deliver 2,242,753 shares, with a cash compensation calculated at RMB 11.78 per share for any shortfall[19] - The company is currently involved in multiple lawsuits related to financing lease contracts, with the Xi'an Intermediate People's Court rejecting all claims made by the company[15] - The company has initiated legal actions against various parties related to contract disputes, with ongoing updates on the litigation status[16] - The company is facing uncertainty regarding the recovery of performance compensation for the year 2018 due to ongoing arbitration proceedings[19] - The company has noted that its former vice president, Liang Xicai, is under criminal investigation for alleged embezzlement, which may impact financial reporting[17] - The company is appealing a court ruling that could significantly impact its management structure and control stability, although it does not expect this to affect current or future profits materially[20] Asset and Equity Changes - Total assets at the end of the reporting period were ¥2,600,792,186.69, a decrease of 2.87% from the end of the previous year[5] - The equity attributable to shareholders decreased by 3.94% to ¥2,059,024,150.67 compared to the end of the previous year[5] - The company's total liabilities as of September 30, 2021, were RMB 540,645,716.84, slightly up from RMB 533,105,022.97 at the end of 2020, indicating a marginal increase of about 1%[25] - The total equity attributable to the owners of the parent company decreased to RMB 2,059,024,150.67 from RMB 2,143,437,756.92, representing a decline of approximately 3.9%[25] - The company reported a net loss of RMB 1,114,968,315.04 as of September 30, 2021, compared to a net loss of RMB 1,078,951,099.45 at the end of 2020[25] Investments and Repurchases - The company repurchased a total of 7,758,700 shares, accounting for 1.71% of the total share capital, with a total transaction amount of RMB 48,396,390.66[21] - The company completed the transaction of the equity transfer of Pearl Assets, receiving a total of RMB 303,241,524.00 in principal and RMB 7,842,291.24 in interest, fully settling the payment[21] - The company is implementing new leasing standards effective January 1, 2021, which may impact financial reporting[37] - The company has ongoing investments in fixed assets and construction projects, with CNY 22,417,456.24 allocated to construction in progress[35] Management and Expenses - The company reported a decrease in management expenses to $79.73 million from $97.27 million, a reduction of approximately 18.9%[27]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥368,050,497.79, representing a 16.63% increase compared to ¥315,580,038.20 in the same period last year[21]. - The net profit attributable to shareholders was a loss of ¥21,925,534.04, an improvement of 58.98% from a loss of ¥53,453,901.94 in the previous year[21]. - The basic earnings per share improved to -¥0.05 from -¥0.12, reflecting a 58.33% increase[21]. - The company reported a total comprehensive loss of ¥21,925,534.04 for the first half of 2021, compared to a loss of ¥53,453,901.94 in the same period of 2020[164]. - The net loss for the first half of 2021 was ¥21,851,474.22, an improvement from a net loss of ¥53,406,452.95 in the same period of 2020, representing a reduction of 59.0%[163]. - The company reported an operating profit of ¥-9,039,481.52 for the first half of 2021, compared to ¥-64,455,706.27 in the first half of 2020, indicating a significant improvement[163]. Cash Flow and Investments - The net cash flow from operating activities decreased significantly by 91.20%, amounting to ¥2,662,791.59 compared to ¥30,269,357.81 in the same period last year[21]. - Investment activities generated a net cash flow of ¥51,694,913.67, a substantial increase of 108.92% compared to the previous year, due to cash recovered from investments[42]. - The total cash inflow from investment activities was CNY 754,997,905.87, compared to CNY 70,666,294.33 in the previous year, representing an increase of approximately 964.5%[170]. - The cash inflow from operating activities totaled CNY 354,899,731.34, while cash outflows amounted to CNY 352,236,939.75, resulting in a net cash flow of CNY 2,662,791.59[169]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,591,458,203.86, down 3.22% from ¥2,677,542,017.40 at the end of the previous year[21]. - The total liabilities decreased slightly from CNY 533,105,022.97 to CNY 517,269,075.31, a decline of about 3.0%[155]. - The equity attributable to shareholders decreased from CNY 2,143,437,756.92 to CNY 2,073,115,831.22, a decrease of approximately 3.3%[155]. - The company's inventory decreased from CNY 34,484,453.80 to CNY 33,623,857.67, a decline of approximately 2.5%[153]. Operational Strategies - The company is focusing on key specialties such as geriatrics, cardiology, oncology, rehabilitation, and orthopedics to enhance service quality and expand its market presence[34]. - The company is implementing refined management practices to improve operational efficiency and reduce costs[32]. - The company is responding to changes in medical insurance policies and the ongoing pandemic by enhancing service quality and innovating service delivery[33]. Risks and Challenges - The company faces significant risks and has outlined measures to address these in the report[5]. - The company faces risks related to policy changes in the healthcare industry, which may impact service quality and operational strategies[60]. - Increased competition in the healthcare sector is expected due to rising consumer demand for diverse and high-quality medical services[61]. - The company is actively addressing risks associated with public health emergencies, ensuring compliance with ongoing pandemic prevention measures[62][63]. Community Engagement and Social Responsibility - The company actively engages in community service, providing free medical consultations and health education, with over 500 individuals served in the first half of 2021[85]. - The company has established a fever clinic and PCR laboratory to support local pandemic control efforts[87]. - The company has demonstrated a commitment to social responsibility by participating in blood donation campaigns and health initiatives[88]. Legal Matters - Legal proceedings related to compensation obligations are ongoing, with uncertainties regarding the recovery of performance guarantees[65]. - The company is involved in ongoing litigation related to financing lease contracts, with appeals filed against lower court rulings[69]. - The company has recognized a provision for expected liabilities amounting to RMB 113,409,224.90 related to a financing lease dispute[98]. - The company is currently involved in multiple lawsuits related to financing lease agreements, with significant amounts at stake, including 4,512.4 million CNY in one case[102]. Shareholder Matters - The company plans not to distribute cash dividends or issue bonus shares[6]. - The company has commitments from major shareholders to not transfer their shares for 36 months post-issuance, ensuring stability in shareholding[91]. - The company has a structured plan for share lock-up periods to maintain investor confidence[91]. Management and Governance - The company has not experienced any changes in its board of directors or senior management during the reporting period[75]. - The company is committed to enhancing investor relations and transparency through various communication channels[84]. - The financial statements were prepared in accordance with the accounting standards issued by the Ministry of Finance, ensuring compliance and accuracy[194].

Financial Performance - The company's operating revenue for 2020 was ¥724,243,049.01, representing a decrease of 16.96% compared to ¥872,197,431.92 in 2019[16]. - The net profit attributable to shareholders was -¥314,501,943.35, an improvement of 72.65% from -¥1,149,993,756.95 in the previous year[16]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥267,074,741.63, showing a 74.55% improvement from -¥1,049,506,007.43 in 2019[16]. - The net cash flow from operating activities increased by 36.63% to ¥131,665,941.48, compared to ¥96,369,253.05 in 2019[16]. - The basic earnings per share improved to -¥0.69, a 72.73% increase from -¥2.53 in the previous year[16]. - The diluted earnings per share for 2020 was -0.69 CNY, an improvement of 72.73% compared to -2.53 CNY in 2019[18]. - The total assets decreased by 9.79% from 2,968,039,315.95 CNY in 2019 to 2,677,542,017.40 CNY in 2020[18]. - The net assets attributable to shareholders decreased by 13.19% from 2,469,026,819.95 CNY in 2019 to 2,143,437,756.92 CNY in 2020[18]. - The operating revenue for 2020 was 724,243,049.01 CNY, down from 872,197,431.92 CNY in 2019, primarily due to a decline in medical service income[18]. - The company reported a net profit attributable to shareholders of CNY -31.45 million, a reduction in losses by 72.65% compared to the previous year[41]. Strategic Transformation - The company has undergone a strategic transformation to focus on high-quality medical services since 2016, expanding its business from pearl farming to include hospital management[16]. - The company completed the divestment of its pearl-related assets, solidifying its position in the medical services sector[16]. - The company is committed to enhancing its operational capabilities and expanding its market presence in the healthcare industry[16]. - The company aims to expand its medical service offerings and enhance brand influence through improved service quality and community partnerships[28]. - The company is positioned to benefit from the upcoming nationwide implementation of DRG and DIP payment methods, which will reshape the survival environment for comprehensive hospitals[30]. Impact of COVID-19 - The pandemic significantly impacted the healthcare system, leading to a sharp decline in outpatient and inpatient numbers, affecting overall hospital revenues[29]. - The company faced a significant decline in hospital business volume due to the pandemic, impacting operational performance[79]. - The company’s net profit for 2020 was significantly impacted by the COVID-19 pandemic, affecting the operational performance of its hospitals[96]. Legal and Compliance Issues - The audit report for the fiscal year 2020 included a reserved opinion, indicating areas of concern that investors should be aware of[4]. - The company is currently involved in ongoing litigation related to financing lease disputes, with appeals filed against unfavorable court rulings[90][91]. - The company is facing legal challenges related to the recovery of funds from the bank, which may impact its financial position in the short term[74]. - The company has taken legal actions to secure its financial interests against Kanghan Investment, including asset freezes and performance guarantees[103]. - The company is involved in multiple lawsuits related to financing lease contracts, with one case pending a final judgment[118]. Operational Challenges - The company reported a significant decline in hospital business volume due to the pandemic, leading to operational costs being heavily impacted, with fixed operating costs comprising a large proportion of total costs[69]. - The company is facing medical talent loss or shortage risks and plans to retain professionals through competitive compensation and talent exchanges[89]. - The company has not made any significant changes to its major asset measurement attributes during the reporting period[62]. Community Engagement and Social Responsibility - The company emphasized patient safety management and improved service quality through a multi-dimensional evaluation system, aiming to reduce medical errors and enhance patient satisfaction[153]. - The company provided rehabilitation services to approximately 300 disabled individuals and 200 disabled children in 2020, achieving a rehabilitation satisfaction rate of 98%[155]. - The company actively engaged in community rehabilitation services, conducting around 90 home rehabilitation sessions and 200 community rehabilitation sessions in 2020[155]. - The company is committed to environmental protection and does not belong to the list of key pollutant discharge units published by local environmental protection departments[157]. - The company emphasized its commitment to social responsibility, focusing on protecting the rights of creditors, employees, and minority shareholders[150]. Financial Management and Investments - The company has committed to invest ¥62,600 million in the construction of the Jianhua Hospital outpatient comprehensive building, with only 6.10% of the project completed as of the reporting date[68]. - The company has utilized ¥8,299 million of the ¥8,300 million allocated for working capital, achieving a utilization rate of 99.99%[68]. - The company reported a total investment of 62,600 million RMB for the construction of the internal medicine outpatient comprehensive building project, with only 3,820.79 million RMB (6.10%) invested as of March 31, 2020, leading to a temporary suspension of the project due to insufficient business volume in Qiqihar city[79]. - The company has not engaged in high-risk entrusted financial management that is not principal-protected[144]. Shareholder and Equity Information - The total number of shares is 454,856,365, with 83,948,797 shares (18.46%) under limited sale conditions and 370,907,568 shares (81.54%) under unrestricted sale conditions[165]. - The company has not issued any new shares or conducted any share buybacks during the reporting period[168]. - The company reported no changes in its controlling shareholder during the reporting period[172]. - The actual controller, Chen Xiaoying, has not changed during the reporting period, maintaining control over the company[173]. Future Outlook and Growth Plans - The company projects a revenue growth of 20% for the upcoming fiscal year, targeting 1.44 billion RMB in 2021[188]. - New product development includes the launch of a cutting-edge medical device expected to generate an additional 200 million RMB in revenue in 2021[188]. - The company plans to enhance its digital marketing efforts, allocating an additional 50 million RMB to boost online engagement and sales[188]. - The company is focused on expanding its market presence through various financial products and services[146]. - The company is exploring potential mergers and acquisitions to strengthen its market position[146].

Financial Performance - The company's revenue for Q1 2021 was ¥161,392,113.23, representing a 5.80% increase compared to ¥152,545,362.35 in the same period last year[8] - The net profit attributable to shareholders was -¥24,053,643.08, an improvement of 34.07% from -¥36,481,490.93 year-over-year[8] - The basic and diluted earnings per share were both -¥0.05, showing a 37.50% improvement from -¥0.08 in the same quarter last year[8] - The company reported a net profit of -24,053,600 RMB for Q1 2021, and expects a net profit between -45,000,000 RMB and -55,000,000 RMB for the first half of 2021[35] - The company reported a net loss of CNY 1,103,004,742.53 in retained earnings, worsening from a loss of CNY 1,078,951,099.45[49] - The company reported a significant increase in non-current liabilities, which rose by 44,353,515.15 CNY to 229,254,167.28 CNY[71] Cash Flow - The net cash flow from operating activities was -¥9,888,396.53, which is a decline of 31.01% compared to -¥7,547,618.02 in the previous year[8] - The company reported cash and cash equivalents at the end of Q1 2021 amounting to 276,245,532.99, down from 737,692,806.59 at the end of the previous year[65] - Cash received from investment recoveries rose by 200.00% to RMB 150,000,000.00, mainly from the redemption of financial products[16] - The net cash flow from investment activities was -35,194,627.87 CNY, with total cash outflow from investment activities amounting to 146,649,505.89 CNY[68] - The net cash flow from financing activities was -29,755,500.00 CNY, with total cash outflow from financing activities also at 29,755,500.00 CNY[68] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,679,506,200.77, a slight increase of 0.07% from ¥2,677,542,017.40 at the end of the previous year[8] - The company's current assets decreased to CNY 1,048,422,132.04 from CNY 1,119,950,091.87, representing a decline of approximately 6.4%[46] - The total liabilities of the company rose to CNY 588,846,834.73 from CNY 533,105,022.97, marking an increase of about 10.5%[48] - The total equity attributable to shareholders decreased to CNY 2,089,628,613.84 from CNY 2,143,437,756.92, a decline of approximately 2.5%[49] - The company's total current liabilities increased to 368,574,594.44 CNY, indicating a rise in short-term financial obligations[71] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 14,779[12] - The largest shareholder, Chen Xiaying, holds 17.06% of the shares, with a total of 77,616,997 shares[12] - The company did not engage in any repurchase transactions among the top ten shareholders during the reporting period[13] - The company repurchased shares amounting to RMB 29,755,500.00 during the reporting period[16] - The company repurchased a total of 7,758,700 shares, accounting for 1.71% of the total share capital, with a total transaction amount of RMB 48,396,390.66[23] Legal Proceedings - The company is involved in ongoing legal proceedings related to various disputes, which may impact future financial performance[18][19][21] - The company has initiated legal proceedings against the Industrial and Commercial Bank of China regarding the forced deduction of RMB 24.969 million from its fundraising account[22] - The company is appealing a court ruling related to a dispute with 富浙资本, which has not yet been resolved[23] - The company has received a civil lawsuit from 富浙资本 regarding a company resolution dispute, which is still pending judgment[23] Investments and Projects - Long-term equity investments of RMB 20,000,000.00 were made in a "brain-computer interface" project company[16] - The company established a joint venture for the "brain-computer interface" project with a registered capital of RMB 50 million, contributing RMB 20 million, which represents 40% of the total[24] - The company has invested RMB 55,000,000 in bank wealth management products using temporarily idle raised funds[37] - The company has temporarily suspended the construction of the internal medicine outpatient comprehensive building at Jianhua Hospital due to insufficient business volume[34] - The company plans to continue the construction of the "Kanghua Hospital Phase II Outpatient Building" project with the remaining funds from the completed Phase II project[34]